Resumen: Objective: The aim of this study was to describe growth during puberty in young people with vertically acquired HIV.
Design: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand.
Methods: One thousand and ninety-four children initiating a nonnucleoside reverse transcriptase inhibitor or boosted protease inhibitor based regimen aged 1-10 years were included. Super Imposition by Translation And Rotation (SITAR) models described growth from age 8 years using three parameters (average height, timing and shape of the growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics associated with these three parameters.
Results: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8, 9.0] years and -1.2 (IQR: -2.3 to -0.2), respectively. Median follow-up was 9.1 (IQR: 6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20-0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years and 1.50 (1.21-1.78) years later in those starting with HAZ less than -3 compared with HAZ at least -1. Later growth spurts in girls resulted in continued height growth into later adolescence. In boys starting ART with HAZ less than -1, growth spurts were later in children starting ART in the oldest age group, but for HAZ at least -1, there was no association with age. Girls and boys who initiated ART with HAZ at least -1 maintained a similar height to the WHO reference mean.
Conclusion: Stunting at ART initiation was associated with later growth spurts in girls. Children with HAZ at least -1 at ART initiation grew in height at the level expected in HIV negative children of a comparable age. Idioma: Inglés DOI: 10.1097/QAD.0000000000002294 Año: 2019 Publicado en: AIDS (London, England) 33, 12 (2019), 1897-1910 ISSN: 0269-9370 Factor impacto JCR: 4.511 (2019) Categ. JCR: INFECTIOUS DISEASES rank: 19 / 93 = 0.204 (2019) - Q1 - T1 Categ. JCR: VIROLOGY rank: 7 / 37 = 0.189 (2019) - Q1 - T1 Categ. JCR: IMMUNOLOGY rank: 49 / 158 = 0.31 (2019) - Q2 - T1 Factor impacto SCIMAGO: 2.447 - Immunology (Q1) - Infectious Diseases (Q1) - Immunology and Allergy (Q1)